Valuation: Galapagos NV

Market Cap 1.69B 1.93B 1.93B 1.56B 1.46B 2.75B 183B 2.81B 18.81B 7.26B 90.21B 7.26B 7.1B 313B P/E 2026 *
-8.84x
P/E 2027 * -10.2x
Enterprise Value -961M -1.1B -1.1B -887M -828M -1.56B -104B -1.59B -10.67B -4.12B -51.19B -4.12B -4.03B -178B EV / Sales 2026 *
-6.39x
EV / Sales 2027 * -5.69x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 43 06/07/2025
Chief Tech/Sci/R&D Officer 61 07/06/2026
Director TitleAgeSince
Director/Board Member 63 21/10/2019
Director/Board Member 49 06/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%+7.83%-4.50%+3.17% 46.2B
+1.93%+12.82%+408.45%+613.42% 38.71B
-0.64%+13.10%+20.43%-14.29% 31.9B
+2.63%+5.52%+18.47%+60.59% 31.12B
+8.02%+5.23%+17.67%+35.36% 23.77B
-0.52%+13.72% - - 16.2B
-0.60%+16.37%+68.94%+125.69% 15.05B
-1.13%+7.40%+12.81%+20.67% 13.74B
-0.67%+6.42%+104.41%+96.45% 13.42B
Average +1.02%+10.60%+80.84%+117.63% 25.57B
Weighted average by Cap. +1.29%+10.07%+92.86%+138.52%

Financials

2026 *2027 *
Net sales 150M 172M 172M 139M 130M 244M 16.25B 250M 1.67B 645M 8.01B 645M 631M 27.83B 132M 151M 151M 122M 114M 214M 14.27B 219M 1.47B 567M 7.04B 567M 554M 24.43B
Net income -261M -298M -298M -241M -225M -423M -28.15B -433M -2.9B -1.12B -13.89B -1.12B -1.09B -48.22B -145M -166M -166M -134M -125M -236M -15.68B -241M -1.61B -623M -7.73B -623M -609M -26.85B
Net Debt -2.65B -3.03B -3.03B -2.45B -2.29B -4.31B -287B -4.41B -29.49B -11.38B -141B -11.38B -11.13B -491B -2.44B -2.79B -2.79B -2.26B -2.11B -3.97B -264B -4.06B -27.16B -10.49B -130B -10.49B -10.26B -452B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B